The road to a 'miracle drug': How Ultragenyx and partners found their way to the newest rare disease treatment
The FDA on Tuesday approved the drug, a liquid oil branded as Dojolvi, to treat genetic fatty acid oxidation disorders that can kill babies in their sleep.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Ron Leuty Source Type: news
More News: Babies | Biotechnology | Genetics | Health Management | Rare Diseases | Sleep Disorders | Sleep Medicine